Atox Bio
develops novel therapeutics for the treatment of inflammatory diseases... Read moreAtox Bio
develops novel therapeutics for the treatment of inflammatory diseases... Read more
News
Dec 29, 2020
The Business Journals: Raleigh/Durham
Atox Bio: Durham drugmaker with treatment for flesh-eating disease seeks federal approval
Dec 12, 2020
FE Investegate
Atox Bio: Arix Bioscience PLC : Atox Bio announces FDA acceptance of New Drug Application
Jul 10, 2020
Unique Finance
Atox Bio: Atox Bio Announces a Positive Effect of Reltecimod on Resolution of Organ Dysfunction in Phase 3 ACCUTE Trial for Patients with Necrotizing Soft Tissue Infection ("Flesh Eating Disease")
Jul 10, 2020
centralcharts
Press Release: Atox Bio : Arix Bioscience Plc - Atox Bio plans NDA submission for Q3 2020
Jun 18, 2019
PR Newswire
Press Release: Atox Bio : Atox Bio Announces Exercise by BARDA of Next Option Period to Support Continued Development of Reltecimod for NSTI
Nov 29, 2018
BioPortfolio
Atox Bio: Atox Bio Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13112018 Prices from USD $250
Sep 25, 2018
PR Newswire
Press Release: Atox Bio : Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study of Reltecimod in Necrotizing Soft Tissue Infections
Jul 31, 2018
BioPortfolio
Atox Bio: Atox Bio Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250
May 30, 2018
PharmiWeb
Atox Bio: Atox Bio Announces Enrollment of First Patient in Phase 2 Study of Acute Kidney Injury (AKI)
Apr 05, 2018
BioPortfolio
Atox Bio: Atox Bio Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 19022018 Prices from USD $250
Atox Bio Competitors
1
2
3
4
5
6
7
8
9
10